Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
Stereochemistry–activity relationship of orally active tetralin S1P agonist prodrugs
作者:Bin Ma、Kevin M. Guckian、Edward Yin-Shiang Lin、Wen-Cherng Lee、Daniel Scott、Gnanasambandam Kumaravel、Timothy L. Macdonald、Kevin R. Lynch、Cheryl Black、Sowmya Chollate、Kyungmin Hahm、Gregg Hetu、Ping Jin、Yi Luo、Ellen Rohde、Anthony Rossomando、Robert Scannevin、Joy Wang、Chunhua Yang
DOI:10.1016/j.bmcl.2010.02.006
日期:2010.4
Modifying FTY720, an immunosuppressant modulator, led to a new series of well phosphorylated tetralin analogs as potent S1P1 receptor agonists. The stereochemistry effect of tetralin ring was probed, and (-)(R)-2-amino-2-((S)-6-octyl-1,2,3,4-tetrahydronaphthalen-2-yl)propan-1-ol was identified as a good SphK2 substrate and potent S1P1 agonist with good oral bioavailability. (C) 2010 Elsevier Ltd. All rights reserved.